Luteal phase supplementation in assisted reproduction Pregnancy and Childbirth
Conditions
Interventions
All the patients are going to have a mild ovarian stimulation protocol:
rFSH will be started at a dose of 75-150 IU on the base of AMH level. GnRH antagonist (0.25 mg/day) will be administered when t
Group B will receive a combination of vaginal administration of a gel of micronized progesterone (90 mg/day) and oral dydrogesterone 10 mg twice a day for luteal phase support. The duration of the tre
follow-up will be around 9 months for each patient, from the established pregnancy to the delivery.
Sponsors
One Day Medical Center srl
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Infertility attributable to tubal factors, moderate endometriosis, male factor, or idiopathic infertility 2. Serum hormonal profile within the normal range (AMH >1 ng/ml) 3. Regular menstrual cycles 4. The presence of a normal uterine cavity 5. Body mass index (BMI) of 20–26 kg/m²
Exclusion criteria
Exclusion criteria: 1. Infertility attributable to genetic factors or severely reduced ovarian reserve 2. Serum hormonal profile showing a reduced ovarian reserve (AMH 26 kg/m²
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy measured using a blood test to evaluate the level of human chorionic gonadotropin (hCG), which indicates the eventual embryo implantation and pregnancy, 14 days after embryo replacement in the patient's uterus | — |
Secondary
| Measure | Time frame |
|---|---|
| Embryo implantation rate measured using ultrasonography at 4 weeks following a positive hCG test to confirm the clinical pregnancy | — |
Countries
Italy
Outcome results
None listed